Related Topics News -

     
 Detail   |   Print 
     
中生製藥GPC3 ADC臨床試驗申請獲FDA批准
2026-09-04T  
中國生物製藥與Cipla就TQB2102訂立獨家授權協議
2026-08-31T  
《大行》野村升中生製藥目標價至8.67元 維持「買入」評級
2026-08-24T  
中國生物製藥創新ActRII A/B單抗獲准開展臨床研究
2026-08-23T  
中生製藥半日升3.6% 獲美銀證券升目標價至7.1元兼上調盈測
2026-08-21T  
《大行》大和:中國生物製藥中期經調整純利遠超預期 目標價升至7.2元
2026-08-20T  
《大行》花旗:中生製藥中期盈利遠超預期 目標價上調至10.8元
2026-08-20T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.